OR WAIT null SECS
September 17, 2021
Moderna’s newest insights include an overall efficacy review, a study on breakthrough infections, and a study on long-term immunity.
Takeda’s Exkivity (mobocertinib) was approved by FDA for the treatment of patients with lung cancer.
Apellis Pharmaceuticals has announced the top-line results from two Phase III studies, evaluating intravitreal pegcetacoplan as a treatment for geographic atrophy.
GeneQuine Biotherapeutics has chosen Exothera to advance the development of its osteoarthritis gene therapy product candidate, GQ-303.
September 16, 2021
AzurRx’s acquisition of First Wave Bio grants them access to their proprietary niclosamide formulations.
September 14, 2021
Repligen and Navigo’s novel ligand could be the first to address antibody aggregation in low pH elution buffers.
HUTCHMED’s amdizalisib (HMPL-689) received breakthrough therapy designation for the treatment of a subtype of non-Hodgkin’s lymphoma.
September 13, 2021
Boehringer Ingelheim and Twist Bioscience will use Twist’s antibody libraries to discover therapeutic antibody candidates.
September 10, 2021
Janssen’s Invega Hayfera is the first six-month injectable schizophrenia treatment approved by FDA.
September 09, 2021
Moderna announced a collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 at no cost to patients.